title: Frequency of the Amsterdam criteria in a regional German cohort of patients with colorectal cancer.
abstract: Estimates of the colon cancer burden associated with hereditary nonpolyposis colorectal cancer (HNPCC) vary from less than 1 % to more than 5 %. Amsterdam criteria fulfilled within a kindred (classic Amsterdam and Amsterdam II criteria) are widely used to identify patients prone to HNPCC. The present study was initiated to assess the frequency of the Amsterdam criteria within a regional German cohort of 207 patients with a history of colorectal cancer (CRC). Data on individual and family cancer histories were available in 154 patients (73 women, 81 men; mean age at diagnosis 62.4 +/- 13.3 years). A total of 843 first degree relatives have been identified within the kindreds of whom 121 had verified cancers. In 28 of 154 families (18 %), at least one first degree relative of the index patient had CRC. With respect to a typical family history, five kindreds (3.2 %) were likely to suffer from HNPCC on a clinical basis (4 kindreds met the classic Amsterdam criteria and one kindred the Amsterdam II criteria). Testing for microsatellite instability could additionally be performed in 4 of 5 patients who met the Amsterdam criteria and revealed DNA instability in 3 cases. Moreover, a missense mutation of MSH2 (Gly965Asp) was detected in one patient with microsatellite instability. Based on the classic Amsterdam and Amsterdam II criteria approximately 3 % of a regional German cohort of patients with CRC are likely to suffer from HNPCC. However, the final diagnosis of HNPCC can only be established by detection of pathogenic germline mutations within the DNA mismatch repair genes.
authors.affiliation: Medizinische Klinik II, Klinikum der J. W. Goethe-Universität, Frankfurt/Main, Germany. Raedle@em.uni-frankfurt.de
authors.forename: J
authors.initials: J
authors.lastname: Raedle
authors.forename: M
authors.initials: M
authors.lastname: Schaffner
authors.forename: N
authors.initials: N
authors.lastname: Esser
authors.forename: S
authors.initials: S
authors.lastname: Sahm
authors.forename: J
authors.initials: J
authors.lastname: Trojan
authors.forename: S
authors.initials: S
authors.lastname: Kriener
authors.forename: A
authors.initials: A
authors.lastname: Brieger
authors.forename: H
authors.initials: H
authors.lastname: Nier
authors.forename: H
authors.initials: H
authors.lastname: Bockhorn
authors.forename: P L
authors.initials: PL
authors.lastname: Berg
authors.forename: B
authors.initials: B
authors.lastname: Frick
authors.forename: D
authors.initials: D
authors.lastname: Schäfer
authors.forename: S
authors.initials: S
authors.lastname: Zeuzem
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020137:Base Pair Mismatch / Q000235:genetics; D015331:Cohort Studies; D003123:Colorectal Neoplasms, Hereditary Nonpolyposis / Q000175:diagnosis / Q000235:genetics*; D004260:DNA Repair / Q000235:genetics; D004268:DNA-Binding Proteins; D005260:Female; D005787:Gene Frequency / Q000235:genetics; D005820:Genetic Testing / Q000379:methods*; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D051718:MutS Homolog 2 Protein; D020125:Mutation, Missense / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics; D018570:Risk Assessment
chemical_list: D004268:DNA-Binding Proteins; D011518:Proto-Oncogene Proteins; C497172:MSH2 protein, human; D051718:MutS Homolog 2 Protein